Abstract 1590P
Background
The LEGACy project aims to improve personalized medicine for gastric cancer in EU and LATAM populations. A hospital-based registry was implemented to compare these populations as a potential tool to plan prevention and treatment strategies providing real-world data.
Methods
A retrospective observational cohort design was used. Survival estimates were determined using actuarial Kaplan-Meier curves. Comparison was performed with the loge-rank test, and differences were considered statistically significant for P values .05.
Results
A total of 689 patients diagnosed with GC from 11/2018 to 04/2021 were included. Country and clinical characteristics are shown in the table. Both cohorts had the body as the most common site reported (34.4% for EU and 51% for LATAM). The most used method for staging was computed tomography for both cohorts, but 6.9% of the LATAM population had a PET/TC instead. The staging at diagnose for LATAM was lower than for the EU population (2.8% and 17.4% respectively). Intestinal histological subtype was the most common (41.9% and 46.3% reported by EU and LATAM), while diffuse subtype was 44.9% for LATAM and 21.3% for EU population. Among patients tested for HER2, 12.5% were positive in the EU cohort and 13.8% in the LATAM cohort. For both cohorts, the most common site of HER2 positive was the GOJ. Surgery was reported in 43.4% of EU population and 48.9% in the LATAM cohort. Systemic treatment with curative intention was indicated in 50.7% in the EU cohort and 46.4% of the LATAM cohort. The most frequent scheme indicated was platinum-based (42.6% and 84.8% for EU and LATAM). Considering both cohorts only 14.4% of the patients got a 2° line of treatment and 3% of the patients received a 3° line. After using cox regression analysis, no difference in overall survival was reported, with a median of 10.9 months.
Table: 1590P
Characteristic | EU Cohort (n: 407) | LATAM Cohort (n: 282) |
Age - Median y [IQR] | 70.50 [61.00, 78.00] | 63.00 [53.00, 71.00] |
Sex - n (%) | ||
Male | 243 (59.9%) | 166 (59.1%) |
Country - n | ||
Argentine | 67 | |
Chile | 112 | |
Mexico | 70 | |
Netherlands | 159 | |
Paraguay | 31 | |
Portugal | 124 | |
Spain | 121 | |
ECOG n (%) | ||
0 | 45 (21.1%) | 61 (27.7%) |
1 | 110 (51.6%) | 116 (52.7%) |
≥2 | 47 (22.1%) | 43 (19.9%) |
Conclusions
Although the limitations of hospital-based registry analysis, this study have provided valuable insights into clinical characteristics and treatment approaches of EU and LATAM populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Union’s Horizon 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701P - Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
Presenter: Miquel Serra-Burriel
Session: Poster session 22
1702P - Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Presenter: Jeroen W. G. Derksen
Session: Poster session 22
1703P - Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
Presenter: Ariadna Tibau
Session: Poster session 22
1704P - Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Presenter: Molto Consolacion
Session: Poster session 22
1705P - Therapeutic value of first vs supplemental indications of drugs in the US and Europe (2011-2020): Retrospective cohort study
Presenter: Kerstin Vokinger
Session: Poster session 22